Disappearance of a highly unusual clone, 46,XY,del(7)(p12),t(9;22)(q34;q11) in chronic myeloid leukemia after treatment with recombinant interferon and cytosine arabinoside.
A patient with the typical features of the stable phase of chronic myeloid leukemia (CML) displayed two karyotypically related subclones. In addition to the t(9;22), cells from one clone contained a deletion of the short arm of chromosome 7, del(7)(p12), [46,XY,del(7)(p12),t(9;22)(q34;q11)]; the other contained only the standard translocation [46,XY,t(9;22)(q34;q11)]. Cells with a deletion of the short arm of chromosome 7 at band p12 as the only additional abnormality have not been observed previously in CML. Conventional chemotherapy with hydroxyurea and then with recombinant interferon-alpha (rIFN-alpha) did not reduce the population of either subclone. However, after treatment with a combination of rIFN-alpha and low-dose cytosine arabinoside (LoDac) continuously infused subcutaneously (s.c.), cells from the clone with the deleted chromosome 7 disappeared and normal metaphases were demonstrable.
Christodoulidou
F
F
Division of Hematology/Oncology, Long Island College Hospital--SUNY Health Science Center, Brooklyn 11201.
Silver
R T
RT
Macera
M J
MJ
Verma
R S
RS
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002869:Chromosome Aberrations; D002871:Chromosome Banding; D002872:Chromosome Deletion; D002892:Chromosomes, Human, Pair 22; D002897:Chromosomes, Human, Pair 7; D002899:Chromosomes, Human, Pair 9; D003561:Cytarabine / Q000008:administration & dosage; D017353:Gene Deletion; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics* / Q000628:therapy; D008297:Male; D011994:Recombinant Proteins / Q000008:administration & dosage; D014178:Translocation, Genetic
D016898:Interferon-alpha; D011994:Recombinant Proteins; D003561:Cytarabine